CURE - Oncology & Cancer News for Patients & Caregivers
CURE - Oncology & Cancer News for Patients & Caregivers
Spotlight
BlogsBreast Cancer Webinar SeriesCancer HorizonsClinical Trial CornerHeal®PublicationsVideos
Cancer Type
View MoreBladderBreastCLLKidneyLungMCLOvarianProstateSkin
About CURE
Press ReleasesShare Your StoryWrite for CURE
News
Cancer Horizons
All News
Blogs
Caregiving
Diet and Exercise
Financial
Psychosocial
Recipes
Sexual Health
Side Effect
Sponsored
Survivorship
Videos
All Videos
CURE Connections
CURE Expert Connections®
CURE Speaking Out
CURE TV
Educated Patient Sound Bites
On Demand: Webinars
Conferences
Conference Coverage
Conference Listing
Events
CURE Adventures
CURE Awards
Educated Patient In Person Education
Educated Patient Virtual Education
Resources
Advocacy Groups
Art Gallery
Clinical Trial Corner
Heal®
Partners
Podcasts
Publications
Share Your Story
Subscribe
  • About Us
  • Advertise / Support
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • TargetedOnc.com
  • OncLive.com
  • OncNursingNews.com
  • Terms & Conditions
  • Privacy
  • Do Not Sell My Information

© 2025 MJH Life Sciences and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.

Spotlight
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Cancer TypeSee All >
  • Bladder
  • Breast
  • CLL
  • Kidney
  • Lung
  • MCL
  • Ovarian
  • Prostate
  • Skin
About CURE
  • Press Releases
  • Share Your Story
  • Write for CURE
  • About Us
  • Advertise / Support
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • TargetedOnc.com
  • OncLive.com
  • OncNursingNews.com
  • Terms & Conditions
  • Privacy
  • Do Not Sell My Information
  • MJHLS Brand Logo

© 2025 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.

European Lung Cancer Congress

  1. home

Camrelizumab Combo Doubles 5-Year Survival in Phase 3 Lung Cancer Trial

April 2nd 2025, 4:35pm

Article

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a Phase 3 trial.

Tagrisso May Improve Survival in Advanced EGFR-Mutant NSCLC

April 1st 2025, 1:13pm

Article

Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer.

COCOON Trial Regimen Reduces Dermatologic Side Effects in Mutated Lung Cancer

March 31st 2025, 8:00pm

Article

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 trial data showed.

First-line Rybrevant Combo Extends Survival in Advanced Lung Cancer

March 31st 2025, 7:00pm

Article

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

Latest News

The Characterization of GIST: What Patients Should Know

Back to School Time Creates ‘Perfect Storm’ For Families Facing Cancer

Is Resistance Training Safe for Patients With Breast Cancer?

What Patients With GIST Need to Know About Their Disease

View More Latest News